Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

查看全文 作　　者：Meiting [1]Chen;Zhao [1]Wang;Xiaojie [1]Fang;Yuyi [1]Yao;Quanguang [1]Ren;Zegeng [1]Chen;Ying [1]Tian;Fei [1]Pan;Xiaoqian [1]Li;Zhiming [1]Li;Qingqing [1]Cai;He [1]Huang;Tongyu [1,2]Lin

机构地区：[1]Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China;[2]Senior Ward/PhaseⅠClinical Trial Ward,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China

出　　处：《Cancer Biology & Medicine》索引2021年第18卷第3期,共8页

基　　金：supported by grants from the Natural Science Foundation of Guangdong Province,China(Grant No.2019A1515010742)。 摘　　要：Objective:To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma.Methods:We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to September 2019 at Sun Yat-sen University Cancer Center.We studied a dose-modified and long-course R-CODOX-M/IVAC regimen utilizing a low dose of 1.0 g/m2/cycle cyclophosphamide,2 g/m2/cycle methotrexate,4,500 mg/m2/cycle ifosfamide,and 4.0 g/m2/cycle cytarabine.Forty-nine patients with low risk disease underwent 4–6 cycles of dose-modified R-CODOX-M-based chemotherapy.Seventy-four patients with high risk disease underwent 6–8 cycles of dose-modified alternating R-CODOX-M/IVAC regimens.Results:The objective remission was 87.0%.The event-free survival rate and overall survival at 3 years were 81.2%and 92.1%,respectively.Major grade 3–4 adverse events included leukopenia(91.9%),anemia(58.5%),thrombocytopenia(73.2%),and febrile neutropenia(48.8%).A total of 26.0%and 37.4%of patients received red blood cell and platelet transfusions,respectively.We observed 4 cases(3.3%)of septic shock after chemotherapy.Two treatment-related deaths occurred from severe infection.Conclusions:The modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population,with a lower toxicity than standard regimens. 关键词：Sporadic Burkitt lymphoma modified chemotherapy toxicity R-CODOX-M/IVAC adults

相关文献

参考文献（19）
引证文献（1）
耦合文献（4）

参考文献(19)

引证文献(1)

耦合文献(4)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

参考文献(19)

引证文献(1)

耦合文献(4)

用户提示